Boston Scientific Corporation reported net sales of $5.138 billion for the third quarter of 2026, a 1.5 percent increase on a reported, operational, and organic basis compared to the prior year period. The company reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, in the same quarter of 2025. Adjusted earnings per share (EPS) for the quarter were $0.73, compared to $0.75 in the prior year.
Segment performance varied by business area. MedSurg sales grew 0.6 percent, while Cardiovascular sales increased 1.9 percent. Urology sales declined 3.1 percent, and Neuromodulation sales rose 13.0 percent. Geographically, sales increased 4.4 percent in Europe, Middle East and Africa (EMEA) and 16.0 percent in Latin America and Canada (LACA). In contrast, sales in the United States were flat at 0.5 percent, and Asia-Pacific sales declined 1.1 percent.
The company provided updated guidance for the full year and fourth quarter of 2026. Boston Scientific now estimates full-year net sales growth of approximately 4.25 percent on a reported basis and 3.75 percent on an organic basis. Adjusted EPS for the full year is expected to be between $3.16 and $3.18. For the fourth quarter, the company forecasts a decline in net sales of approximately 3.0 percent to 1.0 percent on a reported and organic basis, with adjusted EPS projected to be $0.77 to $0.79.
Recent developments include the commencement of the Elite AF clinical trial for the WATCHMAN Elite Left Atrial Appendage Closure Device. The company also received U.S. Food and Drug Administration (FDA) 510(k) clearances for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite Single-Use Digital Flexible Ureteroscope, as well as an expanded size offering for the SEISMIQ Intravascular Lithotripsy Peripheral Catheter.
